Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck, Bristol, Gilead Are In Discussions For Combo HIV Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck, Bristol-Myers Squibb, and Gilead are in discussion to develop a co-packaged version of three different AIDS drugs for use in the developing world
Advertisement

Related Content

Bristol/Gilead Joint Venture Targets 2005 Filing For HIV Fixed-Dose Combo
Bristol/Gilead Joint Venture Targets 2005 Filing For HIV Fixed-Dose Combo
FDA Combo HIV Therapy Review Process May Delay Availability, Rep. Waxman Says
FDA Combo HIV Therapy Review Process May Delay Availability, Rep. Waxman Says
Gilead Moving Forward On Combo HIV Therapy
Gilead Moving Forward On Combo HIV Therapy
Gilead’s Once-Daily HIV Combo Receives Priority Status; Accelerates Race With GSK
Gilead’s Once-Daily HIV Combo Receives Priority Status; Accelerates Race With GSK
HIV/AIDS NDAs For Fixed-Dose Combination Will Be Exempt From User Fees
HIV/AIDS NDAs For Fixed-Dose Combination Will Be Exempt From User Fees

Topics

Advertisement
UsernamePublicRestriction

Register

PS059430

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel